GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (FRA:RV7) » Definitions » Cyclically Adjusted Revenue per Share

Halozyme Therapeutics (FRA:RV7) Cyclically Adjusted Revenue per Share : €2.56 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was €1.398. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.56 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 31.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 31.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 26.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 27.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Halozyme Therapeutics was 39.10% per year. The lowest was 17.30% per year. And the median was 26.55% per year.

As of today (2024-06-14), Halozyme Therapeutics's current stock price is €45.85. Halozyme Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €2.56. Halozyme Therapeutics's Cyclically Adjusted PS Ratio of today is 17.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Halozyme Therapeutics was 79.55. The lowest was 13.00. And the median was 26.24.


Halozyme Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Cyclically Adjusted Revenue per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.90 1.29 1.84 2.34

Halozyme Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 2.01 2.35 2.34 2.56

Competitive Comparison of Halozyme Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PS Ratio falls into.



Halozyme Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.398/131.7762*131.7762
=1.398

Current CPI (Mar. 2024) = 131.7762.

Halozyme Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.109 100.560 0.143
201409 0.091 100.428 0.119
201412 0.198 99.070 0.263
201503 0.138 99.621 0.183
201506 0.287 100.684 0.376
201509 0.146 100.392 0.192
201512 0.373 99.792 0.493
201603 0.299 100.470 0.392
201606 0.232 101.688 0.301
201609 0.221 101.861 0.286
201612 0.288 101.863 0.373
201703 0.215 102.862 0.275
201706 0.224 103.349 0.286
201709 0.373 104.136 0.472
201712 1.051 104.011 1.332
201803 0.176 105.290 0.220
201806 0.210 106.317 0.260
201809 0.152 106.507 0.188
201812 0.367 105.998 0.456
201903 0.342 107.251 0.420
201906 0.238 108.070 0.290
201909 0.287 108.329 0.349
201912 0.343 108.420 0.417
202003 0.167 108.902 0.202
202006 0.355 108.767 0.430
202009 0.390 109.815 0.468
202012 0.685 109.897 0.821
202103 0.503 111.754 0.593
202106 0.767 114.631 0.882
202109 0.671 115.734 0.764
202112 0.626 117.630 0.701
202203 0.754 121.301 0.819
202206 1.014 125.017 1.069
202209 1.514 125.227 1.593
202212 1.229 125.222 1.293
202303 1.098 127.348 1.136
202306 1.528 128.729 1.564
202309 1.510 129.860 1.532
202312 1.609 129.419 1.638
202403 1.398 131.776 1.398

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Halozyme Therapeutics  (FRA:RV7) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=45.85/2.56
=17.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Halozyme Therapeutics was 79.55. The lowest was 13.00. And the median was 26.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Halozyme Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (FRA:RV7) Business Description

Industry
Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (FRA:RV7) Headlines

No Headlines